Insights into ectodomain shedding as a novel target in natural killer cell-based immunotherapy for cancer
Open Access
- 9 March 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1753470
Abstract
Natural killer (NK) cells are innate lymphocytes that kill cancer cells and produce cytokines/chemokines that drive anti-tumor immune responses. NK cells are controlled by activating and inhibitory receptors, of which some, or their ligands, are regulated by ectodomain shedding, which is a post-translational modification to transform surface proteins into soluble peptides. Although ectodomain shedding is essential for normal development and physiology, it is also an immune suppression mechanism for downregulating activating receptors in NK cells or their ligands in cancer cells. The ectodomain shedding of immune receptors or ligands are therapeutic targets in cancer immunology and peculiarly relevant in NK cells, given how receptor/ligand density tips the balance to the activation or inhibition of NK cell effector functions. Two classical examples are the CD16a Fc gamma-activating receptor and the MICA/B, and B7-H6 cellular stress-induced ligands. CD16a triggers antibody-dependent cellular cytotoxicity (ADCC), but CD16a shedding by ADAM17 can prevent receptor engagement, and, therefore, CD16a shedding is a target to promote the efficacy of Fc-enabled antibodies. CD16a shedding also appears to play a dual role, not only in negatively regulating ADCC but also in terminating the immune synapse to help NK cells disengage and move to the next target cell. Furthermore, stress-induced ligands serve as “kill me” signs on the surface of cancer cells, but the shedding of such ligands enables escape from NK cell recognition. Although the shedding of stress-induced ligands is a mechanism of immune evasion in tumors, novel monoclonal antibodies that inhibit such shedding in a highly specific manner have an outstanding efficacy in preclinical tumor models, and one clone has transitioned to clinical trial phase for potently promoting anti-tumor immunity. We, therefore, review here some of the most impactful discoveries in the ectodomain shedding field with a special focus on NK cells and cancer to help inform the scientific community and help guide the development of novel immunotherapies.Keywords
Funding Information
- National Cancer Institute (R37CA269982, P30CA196521)
- Leukemia and Lymphoma Society (6647-23)
- U.S. Department of War (CA210940, BC241026P1)
- American Lung Association (LCD-1022356)
- American Cancer Society (RSG-24-1188643-01-IBCD)
- Elsa U. Pardee Foundation
This publication has 110 references indexed in Scilit:
- CD16A Shedding Regulates Innate Cell Engager‐Induced Serial Killing by Natural Killer CellsEuropean Journal of Immunology, 2025
- Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle‐associated MICA: Dual role in cancer immunosurveillanceJournal of Extracellular Vesicles, 2022
- NKG2D and MICA/B shedding: a ‘tag game’ between NK cells and malignant cellsClinical & Translational Immunology, 2020
- Deficient Natural Killer Cell NKp30‐Mediated Function and Altered NCR3 Splice Variants in Hepatocellular CarcinomaHepatology, 2019
- Enzymatic inhibition of MICA sheddase ADAM17 by lomofungin in hepatocellular carcinoma cellsInternational Journal of Cancer, 2018
- Shedding of endogenous MHC class I‐related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17International Journal of Cancer, 2013
- Molecular and Cellular Mechanisms of Ectodomain SheddingThe Anatomical Record, 2010
- Identification of the cleavage site involved in production of plasma soluble Fc gamma receptor type III (CD16)European Journal of Immunology, 1998
- Regulation of CD2-Mediated Heterotypic Interactions of Murine T LymphocytesCellular Immunology, 1994
- Membrane anchoring and spontaneous release of CD16 (FcR III) by natural killer cells and granulocytesEuropean Journal of Immunology, 1989